Key statistics
As of last trade, Erasca Inc (ERAS:NSQ) traded at 2.45, 61.92% above the 52 week low of 1.51 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.53 |
---|---|
High | 2.53 |
Low | 2.43 |
Bid | 2.44 |
Offer | 2.45 |
Previous close | 2.54 |
Average volume | 1.68m |
---|---|
Shares outstanding | 282.50m |
Free float | 247.48m |
P/E (TTM) | -- |
Market cap | 717.56m USD |
EPS (TTM) | -0.9207 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 17:13 BST.
More ▼
Announcements
- Erasca Reports First Quarter 2024 Business Updates and Financial Results
- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Erasca to Present at Upcoming Investor Conferences in November
More ▼